Are you measuring engineering success by lines of code — or by the outcomes those lines create?

In this episode of Phi Moments, we move beyond the GenAI hype to explore what real-world adoption actually looks like: measurable ROI, practical implementation, and the Phi Moments that emerge when legacy systems collide with modern AI.

Join Nitin Mathur, AVP of Data Platform and Engineering, Definity, and Mohak Moondra, Global Practice Leader - Data & Cloud, Quantiphi as they unpack how AI is evolving from an experimental add-on to an essential developer co-pilot. Nitin shares Definity’s “stay native” strategy — embedding AI directly within developers’ IDEs to reduce friction — and explains why the future isn’t autonomous AI, but an empowered, human-led “architect of intent.”

Whether you’re modernizing legacy systems or scaling engineering productivity, this conversation offers a practical blueprint for building smarter in the GenAI era.

Visit www.quantiphi.com for more information.

Hosted on Acast. See acast.com/privacy for more information.

Join us for the second episode of the Phi Moments podcast, "Building Next-Gen Platforms for Preclinical Testing," where host Rahul Ramchandra Ganar, Head - Life Sciences, Quantiphi dives into the innovations redefining drug discovery and development. We're joined by exceptional leaders, including Asif Hasan, Co-Founder, Quantiphi, Dr. Subhadra Dravida, Founder & CEO, Transcell Biologics, and Creator of the DART platform, and Dr. Sadanand Vodala, Industry Expert and Clinical Development Lead, Boehringer Ingelheim, moderated by Debraj Dasgupta. The discussion focuses on the critical shift toward faster, safer, and more human-relevant approaches in healthcare.

Explore how stem cell-based platforms, advanced AI, and non-animal methods like DART are transforming our understanding of disease mechanisms. The panelists tackle key industry challenges such as The Consistency Chasm, The Small Data Trap, and The Regulatory Black Box, and discuss how to build robust, explainable AI models for safety and toxicology decisions. Learn about the future of preclinical testing, from the emergence of Digital Twins to Inverse Design, and why the time for enterprise adoption of these ethical, efficient platforms is now.

Visit www.quantiphi.com for more information.

Hosted on Acast. See acast.com/privacy for more information.

What if you could rethink preclinical testing — beyond animal models, beyond limitations? Join us for the first episode of our podcast, "Rethinking Preclinical Testing – The DART Advantage," featuring Dr. Subhadra Dravida, Founder & CEO, Transcell Biologics, as the guest speaker, in a powerful conversation with our host, Barinder Marhok, Global Head – Healthcare & Life Sciences, Quantiphi. Discover the Phi Moment – the breakthrough realization that led to DART, an AI-powered, stem cell-based platform that's rewriting the future of preclinical testing: faster, scalable, and more ethical.

Visit www.quantiphi.com for more information.

Hosted on Acast. See acast.com/privacy for more information.